<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136778">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320722</url>
  </required_header>
  <id_info>
    <org_study_id>2010-P-002049</org_study_id>
    <secondary_id>1R01HL105440</secondary_id>
    <nct_id>NCT01320722</nct_id>
  </id_info>
  <brief_title>Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function</brief_title>
  <acronym>MODERATE</acronym>
  <official_title>Modifiable Effectors of Renin System Activation: Treatment Evaluation (MODERATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that, among non-hypertensive overweight and obese individuals,
      treatment of vitamin D deficiency and lowering uric acid concentrations (by either xanthine
      oxidase inhibition or increased renal excretion) will attenuate renin angiotensin system
      (RAS) activation, improve endothelial function, and lower blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have demonstrated that lower levels of 25-hydroxyvitamin D (25[OH]D) and higher
      concentrations of uric acid are both potentially modifiable factors that are independently
      associated with an increased risk of developing hypertension (high blood pressure) in
      humans. Other investigators have shown that vitamin D supplementation, or lowering uric acid
      with allopurinol, may reduce blood pressure. Animal experiments suggest that activation of
      both the systemic and local kidney-specific renin angiotensin systems (RAS) may be the
      principal mechanism linking 25(OH)D and uric acid with hypertension. In human parallels to
      these animal studies, we have shown in cross-sectional analyses that non-hypertensive
      individuals with lower 25(OH)D and higher uric acid levels have increased activation of
      their systemic and kidney-specific RAS, independent of other factors. However, whether
      vitamin D supplementation or uric acid lowering attenuates RAS activation has never been
      demonstrated in humans. Both lower 25(OH)D and higher uric acid concentrations are also
      associated with endothelial dysfunction in humans, and endothelial function may modulate the
      RAS and provide an alternate mechanism for the development of hypertension. It remains
      unclear, however, whether an intervention to increase 25(OH)D or decrease uric acid levels
      among non-hypertensive adults improves endothelial function; furthermore, it is unknown
      whether treatment of these individuals would lower blood pressure. Determining whether
      treatment of 25(OH)D and uric acid concentrations, per se, can attenuate RAS activation,
      improve endothelial function, and lower blood pressure among nonhypertensive individuals is
      critically important, with implications stretching beyond hypertension prevention, since RAS
      activation, endothelial dysfunction, and blood pressure are also implicated in the pathology
      of cardiovascular and chronic kidney disease. Individuals who are overweight and obese
      (two-thirds of US adults) represent an important population who are known to have lower
      25(OH)D levels, higher uric acid concentrations, activation of the RAS, endothelial
      dysfunction, and an increased risk of hypertension, cardiovascular disease, and chronic
      kidney disease. Interestingly, our preliminary data demonstrate that among overweight and
      obese individuals with normal 25(OH)D or low uric acid levels, adiposity is no longer
      associated with activation of the RAS, suggesting that low 25(OH)D and high uric acid
      concentrations might be mediators of the adverse consequences of overweight and obesity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>kidney specific renin angiotensin system (RAS) activation</measure>
    <time_frame>8 weeks</time_frame>
    <description>measured by the renal plasma flow response to captopril in high sodium balance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>systemic renin angiotensin system (RAS) activation</measure>
    <time_frame>8 weeks</time_frame>
    <description>measured by plasma renin activity and Angiotensin II concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endothelial function</measure>
    <time_frame>8 weeks</time_frame>
    <description>assessed by endothelium-dependent vasodilation using brachial artery ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory Blood Pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>24-hour mean ambulatory blood pressure</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Renal Function</condition>
  <condition>Endothelial Function</condition>
  <condition>Blood Pressure</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probenecid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- vitamin D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- uric acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D ergocalciferol</intervention_name>
    <description>50,000 unit soft gel capsule once per week for 8 weeks</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probenecid</intervention_name>
    <description>500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)</description>
    <arm_group_label>Probenecid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)</description>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo soft gel once per week for 8 weeks</description>
    <arm_group_label>Placebo- vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)</description>
    <arm_group_label>Placebo- uric acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25(OH)D &lt; 20 ng/mL OR Uric acid ≥ 5 mg/dL

          -  Age ≥ 18, ≤ 75 years

          -  BMI ≥ 25

        Exclusion Criteria:

          -  Hypertension, or on BP-lowering medicine

          -  Diabetes

          -  Coronary Heart Disease

          -  estimated glomerular filtration rate (EGFR) &lt;60 mL/min

          -  Kidney stones

          -  Active cancer (except non-melanoma skin cancer)

          -  Pregnant

          -  Taking vitamin D supplements and unwilling to stop

          -  Osteoporosis

          -  Hypo- or hypercalcemia

          -  Hypo- or hyperphosphatemia

          -  Known allergy to ACE-inhibitors

          -  Taking medication for hyperuricemia

          -  Gout, anemia, cirrhosis, active/chronic hepatitis, abnormal aspartate
             aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin levels, or
             anemia

          -  Known allergy to either allopurinol or probenecid

          -  Current use of didanosine, azothioprine, methotrexate, ketoprofen, ketorolac,
             mycophenolate, or ACE-inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Forman, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 1, 2016</lastchanged_date>
  <firstreceived_date>March 21, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>John P. Forman</investigator_full_name>
    <investigator_title>INSTRUCTOR IN MEDICINE, BRIGHAM AND WOMEN'S HOSPITAL</investigator_title>
  </responsible_party>
  <keyword>renin angiotensin system</keyword>
  <keyword>vitamin D</keyword>
  <keyword>uric acid</keyword>
  <keyword>allopurinol</keyword>
  <keyword>probenecid</keyword>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Probenecid</mesh_term>
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
